Xiaobo Wang1, Sharon Zeldin2, Hongxue Shi2, Changyu Zhu2, Yoshinobu Saito2, Kathleen E Corey3, Stephanie A Osganian4, Helen E Remotti5, Elizabeth C Verna2, Utpal B Pajvani6, Robert F Schwabe6, Ira Tabas7. 1. Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: xw2279@columbia.edu. 2. Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA. 3. Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA. 4. Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA. 5. Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA. 6. Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA; Institute of Human Nutrition, Columbia University Irving Medical Center, New York, NY 10032, USA. 7. Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA; Institute of Human Nutrition, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: iat1@columbia.edu.
Abstract
BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is a leading cause of hepatocellular carcinoma (HCC), but mechanisms linking NASH to eventual tumor formation remain poorly understood. Herein, we investigate the role of TAZ/WWTR1, which is induced in hepatocytes in NASH, in the progression of NASH to HCC. METHODS: The roles of hepatocyte TAZ and its downstream targets were investigated in diet-induced and genetic models of NASH-HCC using gene-targeting, adeno-associated virus 8 (AAV8)-H1-mediated gene silencing, or AAV8-TBG-mediated gene expression. The biochemical signature of the newly elucidated pathway was probed in liver specimens from humans with NASH-HCC. RESULTS: When hepatocyte-TAZ was silenced in mice with pre-tumor NASH using AAV8-H1-shTaz (short-hairpin Taz), subsequent HCC tumor development was suppressed. In this setting, the tumor-suppressing effect of shTaz was not dependent of TAZ silencing in the tumors themselves and could be dissociated from the NASH-suppressing effects of shTaz. The mechanism linking pre-tumor hepatocyte-TAZ to eventual tumor formation involved TAZ-mediated induction of the NOX2-encoding gene Cybb, which led to NADPH-mediated oxidative DNA damage. As evidence, DNA damage and tumor formation could be suppressed by treatment of pre-tumor NASH mice with AAV8-H1-shCybb; AAV8-TBG-OGG1, encoding the oxidative DNA-repair enzyme 8-oxoguanine glycosylase; or AAV8-TBG-NHEJ1, encoding the dsDNA repair enzyme non-homologous end-joining factor 1. In surrounding non-tumor tissue from human NASH-HCC livers, there were strong correlations between TAZ, NOX2, and oxidative DNA damage. CONCLUSIONS: TAZ in pre-tumor NASH-hepatocytes, via induction of Cybb and NOX2-mediated DNA damage, contributes to subsequent HCC tumor development. These findings illustrate how NASH provides a unique window into the early molecular events that can lead to tumor formation and suggest that NASH therapies targeting TAZ might also prevent NASH-HCC. LAY SUMMARY: Non-alcoholic steatohepatitis (NASH) is emerging as the leading cause of a type of liver cancer called hepatocellular carcinoma (HCC), but molecular events in pre-tumor NASH hepatocytes leading to HCC remain largely unknown. Our study shows that a protein called TAZ in pre-tumor NASH-hepatocytes promotes damage to the DNA of hepatocytes and thereby contributes to eventual HCC. This study reveals a very early event in HCC that is induced in pre-tumor NASH, and the findings suggest that NASH therapies targeting TAZ might also prevent NASH-HCC.
BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is a leading cause of hepatocellular carcinoma (HCC), but mechanisms linking NASH to eventual tumor formation remain poorly understood. Herein, we investigate the role of TAZ/WWTR1, which is induced in hepatocytes in NASH, in the progression of NASH to HCC. METHODS: The roles of hepatocyte TAZ and its downstream targets were investigated in diet-induced and genetic models of NASH-HCC using gene-targeting, adeno-associated virus 8 (AAV8)-H1-mediated gene silencing, or AAV8-TBG-mediated gene expression. The biochemical signature of the newly elucidated pathway was probed in liver specimens from humans with NASH-HCC. RESULTS: When hepatocyte-TAZ was silenced in mice with pre-tumor NASH using AAV8-H1-shTaz (short-hairpin Taz), subsequent HCC tumor development was suppressed. In this setting, the tumor-suppressing effect of shTaz was not dependent of TAZ silencing in the tumors themselves and could be dissociated from the NASH-suppressing effects of shTaz. The mechanism linking pre-tumor hepatocyte-TAZ to eventual tumor formation involved TAZ-mediated induction of the NOX2-encoding gene Cybb, which led to NADPH-mediated oxidative DNA damage. As evidence, DNA damage and tumor formation could be suppressed by treatment of pre-tumor NASH mice with AAV8-H1-shCybb; AAV8-TBG-OGG1, encoding the oxidative DNA-repair enzyme 8-oxoguanine glycosylase; or AAV8-TBG-NHEJ1, encoding the dsDNA repair enzyme non-homologous end-joining factor 1. In surrounding non-tumor tissue from human NASH-HCC livers, there were strong correlations between TAZ, NOX2, and oxidative DNA damage. CONCLUSIONS: TAZ in pre-tumor NASH-hepatocytes, via induction of Cybb and NOX2-mediated DNA damage, contributes to subsequent HCC tumor development. These findings illustrate how NASH provides a unique window into the early molecular events that can lead to tumor formation and suggest that NASH therapies targeting TAZ might also prevent NASH-HCC. LAY SUMMARY: Non-alcoholic steatohepatitis (NASH) is emerging as the leading cause of a type of liver cancer called hepatocellular carcinoma (HCC), but molecular events in pre-tumor NASH hepatocytes leading to HCC remain largely unknown. Our study shows that a protein called TAZ in pre-tumor NASH-hepatocytes promotes damage to the DNA of hepatocytes and thereby contributes to eventual HCC. This study reveals a very early event in HCC that is induced in pre-tumor NASH, and the findings suggest that NASH therapies targeting TAZ might also prevent NASH-HCC.
Authors: Mei Xin; Yuri Kim; Lillian B Sutherland; Masao Murakami; Xiaoxia Qi; John McAnally; Enzo R Porrello; Ahmed I Mahmoud; Wei Tan; John M Shelton; James A Richardson; Hesham A Sadek; Rhonda Bassel-Duby; Eric N Olson Journal: Proc Natl Acad Sci U S A Date: 2013-08-05 Impact factor: 11.205
Authors: Thijs J Hagenbeek; Joshua D Webster; Noelyn M Kljavin; Matthew T Chang; Trang Pham; Ho-June Lee; Christiaan Klijn; Allen G Cai; Klara Totpal; Buvana Ravishankar; Naiying Yang; Da-Hye Lee; Kevin B Walsh; Georgia Hatzivassiliou; Cecile C de la Cruz; Stephen E Gould; Xiumin Wu; Wyne P Lee; Shuqun Yang; Zhixiang Zhang; Qingyang Gu; Qunsheng Ji; Erica L Jackson; Dae-Sik Lim; Anwesha Dey Journal: Sci Signal Date: 2018-09-11 Impact factor: 8.192
Authors: Roser Pinyol; Sara Torrecilla; Huan Wang; Carla Montironi; Marta Piqué-Gili; Miguel Torres-Martin; Leow Wei-Qiang; Catherine E Willoughby; Pierluigi Ramadori; Carmen Andreu-Oller; Patricia Taik; Youngmin A Lee; Agrin Moeini; Judit Peix; Suzanne Faure-Dupuy; Tobias Riedl; Svenja Schuehle; Claudia P Oliveira; Venancio A Alves; Paolo Boffetta; Anja Lachenmayer; Stephanie Roessler; Beatriz Minguez; Peter Schirmacher; Jean-François Dufour; Swan N Thung; Helen L Reeves; Flair J Carrilho; Charissa Chang; Andrew V Uzilov; Mathias Heikenwalder; Arun Sanyal; Scott L Friedman; Daniela Sia; Josep M Llovet Journal: J Hepatol Date: 2021-05-13 Impact factor: 25.083
Authors: Changyu Zhu; KyeongJin Kim; Xiaobo Wang; Alberto Bartolome; Marcela Salomao; Paola Dongiovanni; Marica Meroni; Mark J Graham; Katherine P Yates; Anna Mae Diehl; Robert F Schwabe; Ira Tabas; Luca Valenti; Joel E Lavine; Utpal B Pajvani Journal: Sci Transl Med Date: 2018-11-21 Impact factor: 19.319
Authors: Yannick Boege; Mohsen Malehmir; Marc E Healy; Kira Bettermann; Anna Lorentzen; Mihael Vucur; Akshay K Ahuja; Friederike Böhm; Joachim C Mertens; Yutaka Shimizu; Lukas Frick; Caroline Remouchamps; Karun Mutreja; Thilo Kähne; Devakumar Sundaravinayagam; Monika J Wolf; Hubert Rehrauer; Christiane Koppe; Tobias Speicher; Susagna Padrissa-Altés; Renaud Maire; Jörn M Schattenberg; Ju-Seong Jeong; Lei Liu; Stefan Zwirner; Regina Boger; Norbert Hüser; Roger J Davis; Beat Müllhaupt; Holger Moch; Henning Schulze-Bergkamen; Pierre-Alain Clavien; Sabine Werner; Lubor Borsig; Sanjiv A Luther; Philipp J Jost; Ricardo Weinlich; Kristian Unger; Axel Behrens; Laura Hillert; Christopher Dillon; Michela Di Virgilio; David Wallach; Emmanuel Dejardin; Lars Zender; Michael Naumann; Henning Walczak; Douglas R Green; Massimo Lopes; Inna Lavrik; Tom Luedde; Mathias Heikenwalder; Achim Weber Journal: Cancer Cell Date: 2017-09-11 Impact factor: 31.743
Authors: Xiaobo Wang; Mark R Sommerfeld; Kerstin Jahn-Hofmann; Bishuang Cai; Aveline Filliol; Helen E Remotti; Robert F Schwabe; Aimo Kannt; Ira Tabas Journal: Hepatol Commun Date: 2019-07-23